Multiple benefits with multilineage defense¹

LEUKINE^® (sargramostim) significantly reduced the risk of serious and fatal infection vs placebo in a phase 3, multicenter, randomized, double-blind, placebo-controlled study of patients following induction therapy for AML (N=99)^1-3